Douglas S Hawkins

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. pmc Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas
    Douglas S Hawkins
    Seattle Children s Hospital, University of Washington, and Fred Hutchinson Cancer Research Center, Seattle, WA 98015, USA
    Pediatr Blood Cancer 60:1001-8. 2013
  2. ncbi request reprint Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy
    Douglas S Hawkins
    Department of Pediatrics, Children s Hospital and Regional Medical Center, Seattle, Washington 98105, USA
    Cancer 98:2447-56. 2003
  3. pmc [F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults
    Douglas S Hawkins
    Department of Pediatrics, Seattle Children s Hospital, and Department of Orthopedics, University of Washington, Seattle, Washington 98105 0371, USA
    Cancer 115:3519-25. 2009
  4. ncbi request reprint [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors
    Douglas S Hawkins
    Children s Hospital and Regional Medical Center, 4800 Sandpoint Way, Mailstop B 6553, Seattle, WA 98105 0371, USA
    J Clin Oncol 23:8828-34. 2005
  5. ncbi request reprint Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia
    Douglas S Hawkins
    Children s Hospital and Regional Medical Center, Seattle, Washington 98105 0371, USA
    Clin Cancer Res 10:5335-41. 2004
  6. doi request reprint Sarcoma mid-therapy [F-18]fluorodeoxyglucose positron emission tomography (FDG PET) and patient outcome
    Janet F Eary
    University of Washington, UWMC Box 356113, Seattle, WA 98195 E mail address for J F Eary E mail address for E U Conrad
    J Bone Joint Surg Am 96:152-8. 2014
  7. ncbi request reprint Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse
    Blythe Thomson
    Seattle Children s Hospital and Regional Medical Center, Seattle, Washington, USA
    Pediatr Blood Cancer 43:571-9. 2004
  8. pmc COX-2 expression correlates with survival in patients with osteosarcoma lung metastases
    Nidra I Rodriguez
    Department of Pediatrics, Children s Cancer Hospital, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Pediatr Hematol Oncol 30:507-12. 2008
  9. ncbi request reprint Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy
    Scott M Schuetze
    Department of Medicine, University of Washington Medical Center, Seattle, Washington, USA
    Cancer 103:339-48. 2005
  10. pmc Histologic and clinical characteristics can guide staging evaluations for children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee
    Aaron R Weiss
    The Soft Tissue Sarcoma Committee of the Children s Oncology Group, Monrovia, CA Aaron R Weiss, Maine Medical Center, Portland, ME Elizabeth R Lyden and James R Anderson, University of Nebraska Medical Center, Omaha, NE Douglas S Hawkins, Seattle Children s Hospital, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA Sheri L Spunt, St Jude Children s Research Hospital and the University of Tennessee Health Science Center, Memphis, TN David O Walterhouse, Ann and Robert H Lurie Children s Hospital of Chicago, Chicago, IL Suzanne L Wolden, Memorial Sloan Kettering Cancer Center, New York, NY David M Parham, University of Oklahoma Health Sciences Center, Oklahoma City, OK David A Rodeberg, Children s Hospital of Pittsburgh, Pittsburgh, PA Simon C Kao, University of Iowa Hospitals and Clinics, Iowa City, IA and Richard B Womer, The Children s Hospital of Philadelphia, Philadelphia, PA
    J Clin Oncol 31:3226-32. 2013

Collaborators

Detail Information

Publications46

  1. pmc Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas
    Douglas S Hawkins
    Seattle Children s Hospital, University of Washington, and Fred Hutchinson Cancer Research Center, Seattle, WA 98015, USA
    Pediatr Blood Cancer 60:1001-8. 2013
    ..For RMS, COG Phase 3 trials potentially will explore VEGF/mTOR inhibition or chemotherapy interval compression. For NRSTS, a COG Phase 3 trial will explore VEGF inhibition...
  2. ncbi request reprint Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy
    Douglas S Hawkins
    Department of Pediatrics, Children s Hospital and Regional Medical Center, Seattle, Washington 98105, USA
    Cancer 98:2447-56. 2003
    ..The goal of the current study was to define the clinical features and outcome of recurrent osteosarcoma (OS) in children and young adults initially treated with contemporary chemotherapy...
  3. pmc [F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults
    Douglas S Hawkins
    Department of Pediatrics, Seattle Children s Hospital, and Department of Orthopedics, University of Washington, Seattle, Washington 98105 0371, USA
    Cancer 115:3519-25. 2009
    ..To determine the prognostic value of FDG-PET response for progression-free survival (PFS) in osteosarcoma, the authors of this report reviewed the University of Washington Medical Center experience...
  4. ncbi request reprint [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors
    Douglas S Hawkins
    Children s Hospital and Regional Medical Center, 4800 Sandpoint Way, Mailstop B 6553, Seattle, WA 98105 0371, USA
    J Clin Oncol 23:8828-34. 2005
    ..To determine the prognostic value of FDG PET response for progression-free survival (PFS) in ESFTs, we reviewed the University of Washington Medical Center experience...
  5. ncbi request reprint Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia
    Douglas S Hawkins
    Children s Hospital and Regional Medical Center, Seattle, Washington 98105 0371, USA
    Clin Cancer Res 10:5335-41. 2004
    ....
  6. doi request reprint Sarcoma mid-therapy [F-18]fluorodeoxyglucose positron emission tomography (FDG PET) and patient outcome
    Janet F Eary
    University of Washington, UWMC Box 356113, Seattle, WA 98195 E mail address for J F Eary E mail address for E U Conrad
    J Bone Joint Surg Am 96:152-8. 2014
    ..With this background, a prospective clinical study was designed to assess whether tumor FDG uptake levels in the middle of neoadjuvant chemotherapy added additional prognostic information to pre-therapy imaging data...
  7. ncbi request reprint Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse
    Blythe Thomson
    Seattle Children s Hospital and Regional Medical Center, Seattle, Washington, USA
    Pediatr Blood Cancer 43:571-9. 2004
    ..The ability to achieve a durable second remission is complicated by toxicity and resistant disease. We report a novel combination of chemotherapy for relapsed pediatric ALL...
  8. pmc COX-2 expression correlates with survival in patients with osteosarcoma lung metastases
    Nidra I Rodriguez
    Department of Pediatrics, Children s Cancer Hospital, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Pediatr Hematol Oncol 30:507-12. 2008
    ..However, COX-2 expression correlated inversely with disease-specific survival in patients with osteosarcoma lung metastases. Our data indicate that COX-2 expression in metastatic osteosarcoma may have prognostic significance...
  9. ncbi request reprint Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy
    Scott M Schuetze
    Department of Medicine, University of Washington Medical Center, Seattle, Washington, USA
    Cancer 103:339-48. 2005
    ..Serial FDG-PET scans were taken to determine the correlation between FDG uptake and patient outcomes in patients receiving multimodality treatment of extremity sarcomas...
  10. pmc Histologic and clinical characteristics can guide staging evaluations for children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee
    Aaron R Weiss
    The Soft Tissue Sarcoma Committee of the Children s Oncology Group, Monrovia, CA Aaron R Weiss, Maine Medical Center, Portland, ME Elizabeth R Lyden and James R Anderson, University of Nebraska Medical Center, Omaha, NE Douglas S Hawkins, Seattle Children s Hospital, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA Sheri L Spunt, St Jude Children s Research Hospital and the University of Tennessee Health Science Center, Memphis, TN David O Walterhouse, Ann and Robert H Lurie Children s Hospital of Chicago, Chicago, IL Suzanne L Wolden, Memorial Sloan Kettering Cancer Center, New York, NY David M Parham, University of Oklahoma Health Sciences Center, Oklahoma City, OK David A Rodeberg, Children s Hospital of Pittsburgh, Pittsburgh, PA Simon C Kao, University of Iowa Hospitals and Clinics, Iowa City, IA and Richard B Womer, The Children s Hospital of Philadelphia, Philadelphia, PA
    J Clin Oncol 31:3226-32. 2013
    ..To simplify the recommended staging evaluation by correlating tumor and clinical features with patterns of distant metastasis in newly diagnosed patients with embryonal rhabdomyosarcoma (ERMS) or alveolar rhabdomyosarcoma (ARMS)...
  11. ncbi request reprint Fractionated low-dose radiotherapy after myeloablative stem cell transplantation for local control in patients with high-risk neuroblastoma
    Scott M Bradfield
    Department of Pediatric Hematology Oncology, Children s Hospital and Regional Medical Center, Seattle, Washington 98105 5371, USA
    Cancer 100:1268-75. 2004
    ....
  12. doi request reprint Early response as assessed by anatomic imaging does not predict failure-free survival among patients with Group III rhabdomyosarcoma: a report from the Children's Oncology Group
    Abby R Rosenberg
    Seattle Children s Hospital, Seattle, WA, United States Fred Hutchinson Cancer Research Center, Seattle, WA, United States University of Washington, Seattle, WA, United States Electronic address
    Eur J Cancer 50:816-23. 2014
    ..We repeated the same analysis using a more recent clinical trial as an independent cohort of patients with non-metastatic, initially unresected RMS...
  13. ncbi request reprint Survival after recurrence of Ewing's sarcoma family of tumors
    Lisa M Barker
    University of Washington School of Medicine, Seattle, WA, USA
    J Clin Oncol 23:4354-62. 2005
    ..The overall survival (OS) of patients with relapsed Ewing's sarcoma family of tumors (ESFT) is poor, and the relative benefit of high-dose therapy (HDT) is controversial...
  14. doi request reprint Ewing sarcoma/primitive neuroectodermal tumor arising from the adrenal gland in an adolescent
    Jacob Stephenson
    Division of General and Thoracic Surgery, Seattle Children s Hospital and University of Washington, Seattle, Washington 98105, USA
    Pediatr Blood Cancer 57:691-2. 2011
    ..She is currently disease free 14 months after the operation and 3 months off therapy...
  15. ncbi request reprint Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study
    Douglas S Hawkins
    Children s Hospital and Regional Medical Center, Seattle, WA, USA
    Pediatr Blood Cancer 47:790-4. 2006
    ..The Children's Oncology Group conducted a phase II trial of 21-day continuous infusion topotecan to determine the response rate in pediatric patients with recurrent or refractory malignant solid tumors...
  16. doi request reprint Dense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group
    Erin R Rudzinski
    Seattle Children s Hospital, Department of Laboratories, M S OC 8 720, 4800 Sandpoint Way NE, Seattle, WA 98015, USA
    Am J Clin Pathol 140:82-90. 2013
    ..To examine whether the frequency of fusion-negative alveolar rhabdomyosarcoma (ARMSn) increased coincident with changes in the definition of alveolar histology...
  17. ncbi request reprint Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography
    Douglas S Hawkins
    Department of Pediatrics, Children s Hospital and Regional Medical Center, Seattle, Washington 98105, USA
    Cancer 94:3277-84. 2002
    ..To describe the FDG PET imaging characteristics and to determine the correlation between FDG PET imaging and chemotherapy response in children with bone sarcomas, we reviewed our single institution experience...
  18. doi request reprint An evaluation of [F-18]-fluorodeoxy-D-glucose positron emission tomography, bone scan, and bone marrow aspiration/biopsy as staging investigations in Ewing sarcoma
    Erik N Newman
    Office of Academic Affairs, University of Washington School of Medicine, Seattle, Washington 98195 6340, USA
    Pediatr Blood Cancer 60:1113-7. 2013
    ..Each of these staging investigations provides complementary prognostic information, however the optimal combination of staging investigations is not clear...
  19. doi request reprint Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children's Oncology Group (COG) phase II study
    Stephen X Skapek
    Division of Pediatric Hematology Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9063, USA
    Pediatr Blood Cancer 60:1108-12. 2013
    ..We evaluated the safety and efficacy of tamoxifen and sulindac in a prospective phase II study within the Children's Oncology Group...
  20. ncbi request reprint Oral outpatient chemotherapy medication errors in children with acute lymphoblastic leukemia
    James A Taylor
    Department of Pediatrics, University of Washington and Children s Hospital and Regional Medical Center, Seattle, Washington 98195, USA
    Cancer 107:1400-6. 2006
    ....
  21. ncbi request reprint Intensive induction chemotherapy and delayed irradiation in the management of parameningeal rhabdomyosarcoma
    Stephen C Smith
    University of Washington, Department of Radiation Oncology, Seattle, WA 98195 6043, USA
    J Pediatr Hematol Oncol 25:774-9. 2003
    ..To evaluate local control, event-free survival, and overall survival for patients with parameningeal (PM) rhabdomyosarcoma (RMS) treated with intensive chemotherapy and delayed irradiation...
  22. ncbi request reprint Evaluation of early marrow response in childhood aneuploid acute lymphoblastic leukemia: flow cytometric DNA analysis versus standard morphology
    Laura S Finn
    Department of Laboratories, Children s Hospital and Regional Medical Center, University of Washington School of Medicine, Seattle, WA, USA
    Pediatr Dev Pathol 7:39-47. 2004
    ..Prospective studies need to be employed to evaluate the effect of more definitive methods (DNA-FC and FC) of assessing the early response in bone marrows on prognosis...
  23. doi request reprint A novel algorithm for simplification of complex gene classifiers in cancer
    Raphael A Wilson
    Authors Affiliations Division of Hematology Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center and Children s Medical Center, Dallas, Texas Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma Department of Pathology, University of Southern California and Children s Hospital of Los Angeles, Los Angeles, California Department of Pathology and Laboratory Medicine, Nationwide Children s Hospital and Department of Pathology and Pediatrics, The Ohio State University, Columbus, Ohio National Cancer Institute, Bethesda, Maryland Division of Hematology Oncology, Department of Pediatrics, University of Washington and Seattle Children s Hospital, Seattle, Washington Department of Biostatistics, College of Public Health, University of Nebraska Medical Center, Omaha, Nebraska The Section of Pediatric Hematology Oncology, Department of Pediatrics, Department of Pathology, Center for Research Informatics, and The Computation Institute, University of Chicago, Chicago, Illinois
    Cancer Res 73:5625-32. 2013
    ..Our approach can easily be generalized and coupled to existing technical platforms to facilitate the discovery of simplified signatures that are ready for routine clinical use...
  24. ncbi request reprint Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas
    Douglas S Hawkins
    Department of Pediatrics, Children s Hospital and Regional Medical Center, Seattle, Washington 98105, USA
    Cancer 95:1354-65. 2002
    ....
  25. pmc Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivo
    Brianne S Raccor
    Department of Pharmacy, University of Washington, Seattle, WA 98195 7610, USA
    Drug Metab Dispos 40:54-63. 2012
    ..Concomitant chemotherapy agents did not influence 4HCY formation in vitro. We conclude that CYP2B6 genotype is not consistently related to 4HCY formation in vitro or in vivo...
  26. doi request reprint Pegfilgrastim for prevention of chemotherapy-associated neutropenia in pediatric patients with solid tumors
    Scott C Borinstein
    Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Pediatr Blood Cancer 53:375-8. 2009
    ..Pegfilgrastim has similar efficacy to filgrastim in adults, but studies in pediatrics are limited. We report our institutional experience with pegfilgrastim following dose intensive chemotherapy for solid tumors...
  27. pmc The inconvenience of convenience cohorts: rhabdomyosarcoma and the PAX-FOXO1 biomarker
    Abby R Rosenberg
    Division of Pediatric Hematology Oncology, Seattle Children s Hospital, Seattle, WA 98105, USA
    Cancer Epidemiol Biomarkers Prev 21:1012-8. 2012
    ..This review highlights the findings from several clinical correlation studies of the PAX-FOXO1 biomarker and illustrates the challenges of using such methods to draw clinical conclusions...
  28. ncbi request reprint Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies
    Suman Malempati
    Department of Pediatrics, Oregon Health and Science University, Portland, Oregon 97239 3098, USA
    Pediatr Blood Cancer 59:5-10. 2012
    ..This review describes the IRSG and COG experience with RMS, presents the current risk stratification definitions, and provides rationale for the current generation of COG RMS studies...
  29. pmc (18)F-FDG PET in sarcoma treatment response imaging
    Janet F Eary
    University of Washington, Departments of Radiology, Orthopedics, and Pathology Seattle Children s Hospital, Division of Oncology Seattle, WA, USA
    Am J Nucl Med Mol Imaging 1:47-53. 2011
    ..In this review, background and experience in (18)F-FDG PET as a biomarker that successfully identifies tumor response is assessed...
  30. pmc Rhabdomyosarcoma in infants younger than 1 year: a report from the Children's Oncology Group
    Suman Malempati
    Department of Pediatrics, Oregon Health and Science University, Portland, OR 97239 3098, USA
    Cancer 117:3493-501. 2011
    ..Rhabdomyosarcoma (RMS), the most common soft-tissue sarcoma in children, occurs less commonly in infants. Historically, poorer outcomes have been reported for infants diagnosed with RMS than for older children...
  31. ncbi request reprint Survival of tumor megaprostheses replacements about the knee
    Hannah D Morgan
    Department of Orthopaedics and Sports Medicine, University of Washington Medical Center, 1959 NE Pacific Street, Seattle, WA 98195, USA
    Clin Orthop Relat Res 450:39-45. 2006
    ..Aseptic loosening was the most common reason for failure (n = 18/32; 56%). The incidence of failure in tumor megaprostheses is similar to early published literature and the incidence of these failures is highest within the first 3 years...
  32. doi request reprint No evidence of a trial effect in newly diagnosed pediatric acute lymphoblastic leukemia
    Carl Koschmann
    Seattle Children s Hospital, 4800 Sand Point Way NE, Seattle, WA 98105, USA
    Arch Pediatr Adolesc Med 164:214-7. 2010
    ..To determine whether clinical trial enrollment by itself is associated with improved outcome...
  33. ncbi request reprint Prolonged survival after invasive aspergillosis: a single-institution review of 11 cases
    Jessica A Wright
    Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington 98105 0371, USA
    J Pediatr Hematol Oncol 25:286-91. 2003
    ..Case series of IA in the pediatric oncology population are limited but generally report poor overall survival...
  34. ncbi request reprint Influence of age upon Ifosfamide-induced nephrotoxicity
    Jeannine S McCune
    University of Washington Medical Center, Seattle, Washington, USA
    Pediatr Blood Cancer 42:427-32. 2004
    ..Ifosfamide-induced nephrotoxicity is well recognized in children, although it has also been reported in adults. Whether ifosfamide nephrotoxicity is more common in children than in adults is not known...
  35. ncbi request reprint Maternal and birth characteristics and childhood rhabdomyosarcoma: a report from the Children's Oncology Group
    Philip J Lupo
    Department of Pediatrics, Texas Children s Cancer Center, Baylor College of Medicine, Houston, TX, USA
    Cancer Causes Control 25:905-13. 2014
    ..Our objective was to evaluate the associations between maternal and birth characteristics and childhood rhabdomyosarcoma...
  36. doi request reprint What is new in the biology and treatment of pediatric rhabdomyosarcoma?
    Douglas S Hawkins
    aDepartment of Pediatrics, Seattle Children s Hospital, Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, Washington bDivision of Hematology Oncology, Hospital for Sick Children, University of Toronto, Toronto, Canada cDepartment of Pathology, Seattle Children s Hospital, University of Washington School of Medicine, Seattle, Washington, USA
    Curr Opin Pediatr 26:50-6. 2014
    ..The purpose of this review is to highlight some of the advances in the way we think about rhabdomyosarcoma (RMS). Recent outcome and biological analyses have shifted the risk stratification and treatment paradigms for pediatric RMS...
  37. pmc Comparison of genome-wide binding of MyoD in normal human myogenic cells and rhabdomyosarcomas identifies regional and local suppression of promyogenic transcription factors
    Kyle L MacQuarrie
    Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Mol Cell Biol 33:773-84. 2013
    ..These results demonstrate that regional and local silencing of differentiation factors contributes to the differentiation defect in rhabdomyosarcomas...
  38. pmc Malignant progression in two children with multiple osteochondromas
    Gregory A Schmale
    Department of Orthopaedics and Sports Medicine, School of Medicine, University of Washington, Seattle, WA 98195, USA
    Sarcoma 2010:417105. 2010
    ..Both underwent allograft reconstruction of the involved site with no signs of recurrence or metastatic disease at a minimum of four-year follow-up...
  39. ncbi request reprint Metastatic malignant melanoma presenting as pancytopenia in a three-year-old boy
    Susan E Spiller
    Division of Hematology Oncology, Children s Hospital and Regional Medical Center, Seattle, Washington 98105 0371, USA
    Pediatr Blood Cancer 45:60-3. 2005
    ..This case illustrates an unusual presentation of bone marrow failure secondary to malignant melanoma in a young child with symptomatic metastatic marrow infiltration, a rarely reported site of melanoma involvement in adults or children...
  40. ncbi request reprint Pediatric intradural extramedullary synovial sarcoma: case report
    Stephanie Greene
    Department of Neurological Surgery, University of Washington School of Medicine, Children s Hospital and Regional Medical Center, Seattle, Washington, USA
    Neurosurgery 59:E1339; discussion E1339. 2006
    ..This report provides a summary of the literature on this tumor and on tumors arising in this location, as well as a description of this patient's clinical course...
  41. ncbi request reprint Fas expression in lung metastasis from osteosarcoma patients
    Nancy Gordon
    Division of Pediatrics, Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, and Division of Pediatrics Hematology Oncology, Mayo Clinic, Rochester, MN, USA
    J Pediatr Hematol Oncol 27:611-5. 2005
    ..0013). These data indicate that loss of Fas may be one mechanism by which OS cells evade host resistance in the lung. Chemotherapy may induce regression by upregulating Fas...
  42. ncbi request reprint Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group
    Carola A S Arndt
    Mayo Clinic and Foundation, Rochester, Minnesota, USA
    Pediatr Blood Cancer 50:33-6. 2008
    ..Treatment with alternating cycles of non-cross-resistant chemotherapy has been used in a number of diseases with good results...
  43. ncbi request reprint Treatment of metastatic osteosarcoma with the somatostatin analog OncoLar: significant reduction of insulin-like growth factor-1 serum levels
    Patrick J Mansky
    Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 2669, USA
    J Pediatr Hematol Oncol 24:440-6. 2002
    ..Insulin-like growth factor-1 (IGF-1) has been implicated in the growth and/or metastasis of osteosarcoma (OS) and chondrosarcoma based on in vitro and experimental animal studies...
  44. pmc Phase II trial of oral aminopterin for adults and children with refractory acute leukemia
    Peter D Cole
    Department of Pediatric Oncology, The Cancer Institute of New Jersey, New Brunswick, New Jersey 08901, USA
    Clin Cancer Res 11:8089-96. 2005
    ....
  45. doi request reprint Two boys with fragile x syndrome and hepatic tumors
    Juthamas Wirojanan
    Medical Investigation of Neurodevelopmental Disorders, University of California Davis Health System, Sacramento, CA 95817, USA
    J Pediatr Hematol Oncol 30:239-41. 2008
    ..We speculate regarding molecular pathways that might explain the cooccurrence of the 2 conditions. Further examination of a possible functional link between hepatic neoplasia and loss of FMRP is warranted...
  46. ncbi request reprint Delayed radiotherapy following dose intensive chemotherapy for parameningeal rhabdomyosarcoma (PM-RMS) of childhood
    James G Douglas
    Department of Radiation Oncology, University of Washington Affiliated Hospitals, Seattle, WA, United States
    Eur J Cancer 43:1045-50. 2007
    ..To evaluate the local control rates and survival rates of patients with Group III parameningeal rhabdomyosarcoma (PM-RMS) treated with a dose intensive chemotherapy regimen followed by irradiation...